阿帕替尼联合FOLFOXIRI方案治疗不可切除结直肠癌肝转移患者的疗效与安全性观察

Efficacy and safety of apatinib combined with FOLFOXIRI chemotherapy in treating unresectable colorectal cancer with liver metastasis

目的观察阿帕替尼联合FOLFOXIRI方案治疗不可切除的结直肠癌肝转移的疗效及安全性。方法回顾性分析2013年7月至2015年8月广西百色市人民医院收治的40例不可切除的结直肠癌肝转移患者的临床资料,根据治疗方案分为对照组(n=20,FOLFOXIRI方案)与观察组(n=20,阿帕替尼联合FOLFOXIRI方案)。比较两组临床疗效及不良反应发生情况。结果观察组与对照组有效率分别为75.00%应发生率分别为10.00%案治疗不可切除的结直肠癌肝转移疗效确切,安全性良好。

Objectives To study the efficacy and safety of apatinib combined with FOLFOXIRI chemotherapy in treating unresectable colorectal cancer with liver metastasis.Methods This was a retrospective analysis of clinical data of 40 patients with unresectable colorectal cancer with liver metastasis treated in Baise People’s Hospital between July 2013 and August 2015.Patients were divided into control group(n=20),who received FOLFOXIRI chemotherapy,and treatment group(n=20),who received apatinib combined with FOLFOXIRI chemotherapy.Clinical effectiveness and adverse events were compared between the two groups.Results Rate of effectiveness was 75.00%(15/20)in treatment group and 40.00%(8/20)in control group,with significant between-group difference(P<0.05).Incidence of adverse event was 10.00%(2/10)and 40.00%(8/20)in the treatment group and control group,respectively,with significant between-group difference(P<0.05).Conclusion Apatinib combined with systematic high intensity FOLFOXIRI chemotherapy was effective and safe in treating unresectable colorectal cancer with liver metastasis.